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ABSTRACT 
SEROLOGICAL EVIDENCE FOR THE CO-CIRCULATION OF TWO LINEAGES 
OF INFLUENZA D VIRUS IN EQUINE POPULATIONS OF THE MIDWESTERN 
UNITED STATES   
HUNTER THEODORE MAY NEDLAND 
2019 
 
 Influenza D virus (IDV) is a newly described lineage of the Orthomyxoviridae virus 
family that was first isolated from diseased swine in 2011 and has subsequently been 
detected in cattle around the world in 2014. In addition, serological evidence for IDV 
infection in humans has been recently established. Despite all the progress, the full range 
of susceptible hosts for this novel virus has yet to be determined, but includes swine, 
bovine, small ruminants and human. This study was designed to determine if equine is a 
possible host to this newly emerging influenza virus. 364 equine serum samples were 
collected in 2015 from 141 farms within the Midwestern United States. Serum samples 
were examined using hemagglutination inhibition (HI) assay against two established IDV 
lineages (D/OK and D/660) and one IDV-related human ICV lineage (C/JHB). Results of 
this study showed 44 (44/364, 12%) samples positive for antibodies against D/OK, 39 
(39/364, 11%) samples positive for antibodies against D/660, and 41 (41/364,11%) 
samples positive for antibodies against C/JHB. A subset of these samples was further 
confirmed via microtiter neutralization (MN) assay. Our data demonstrated that horses are 
susceptible to two lineages of IDV, and that these viruses were present in equine 
populations throughout multiple Midwestern states of the United States. These findings 
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continue to support the need for further surveillance of IDV viruses in agricultural species 
in order to work toward a better understanding of the full host range and natural reservoirs 
of influenza D virus.   
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Chapter 1: Introduction and Background 
 
 
1. Influenza Virus 
 
 Influenza viruses are a group of pathogens responsible for causing infectious 
disease on a global scale. They belong to the viral family Orthomyxoviridae and make up 
four of the six genera of that family. The four genera of influenza virus are influenza A 
(IAV), influenza B (IBV), influenza C (ICV), and influenza D (IDV). These genera are 
classified by analysis of the differences in their matrix proteins and nucleoproteins [21]. 
Influenza viruses are negative-sense, segmented RNA viruses that require an RNA-
dependent viral RNA polymerase to facilitate replication [5, 11, 42]. These viruses are 
capable of infecting a wide range of hosts including: humans, numerous avian species, 
bovine, swine, canines, equine, small ruminant species, camels, ferrets, cats, seals, and 
whales [23, 57, 58]. Infection with influenza virus causes respiratory or intestinal disease 
in many of these species [3, 10, 18, 24]. This chapter of the thesis will examine influenza 
viruses in the context of epidemiology and disease surveillance, and how that approach is 
applied to influenza C virus and the novel influenza D virus.   
Influenza A and Influenza B 
Influenza A viruses (IAV) and influenza B viruses (IBV) infect a wide range of 
hosts, both mammalian and avian [4, 18, 27, 47, 57]. The genomes of these related 
viruses are made up of eight negative-sense strands of RNA. These genomic segments 
encode for the following proteins: three RNA-dependent RNA polymerase proteins 
known as polymerase acidic protein (PA), polymerase basic protein 1 (PB1), polymerase 
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basic protein 2 (PB2), as well as PB1-F2 (a non-structural protein), hemagglutinin (HA), 
neuraminidase (NA), nucleoprotein (NP), M1 matrix protein, M2 ion-channel protein, 
and two additional non-structural proteins known as NS1 and NS2 [11, 27] 
IAV subtypes are determined by the variety of the HA and NA glycoproteins 
expressed on the surface of the virion [3, 31, 41]. There are sixteen HA subtypes (H1-16) 
and nine NA (N1-9) varieties that can be expressed in combination [27]. This large 
diversity of antigenic potential allows IAV to reach pandemic levels in human 
populations, as humans do not develop immunity through exposure to all subtype 
combinations throughout their lives [26].  
IBV is more restricted in its variety, as it does not re-assort with the highly 
mutable IAV subtypes and does not have any known animal reservoirs, though infection 
has been recorded in seals [20]. Only two antigenically and genetically different varieties 
of IBV have been known to circulate around the world since 1983, known as 
B/Victoria/2/87 and B/Yamagata/16/88 [20, 27]. Though limited in diversity, these 
lineages cause significant disease in humans and cause epidemic outbreaks approximately 
every three years in place of an IAV subtype, and are usually included in the mixture of 
subtypes immunized against in the yearly influenza vaccine [27, 41]. 
IAV and IBV are the primary causes of influenza infection in humans, and are 
responsible for the re-occurring seasonal influenza epidemics as well as the sporadic 
worldwide pandemics [16, 41, 54]. Infection in humans causes general respiratory disease 
with fever, soreness, and lethargy, with the potential to be more serious in the very young 
and very old groups. [6, 30]. Seasonal epidemics and the occasional pandemics attributed 
to influenza infection have significant economic and health-related costs on society, with 
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notable increases in mortality and economic loss associated with influenza outbreaks [2, 
12, 36, 46].  
Influenza C Virus 
 Influenza C virus (ICV) differs genetically from IAV and IBV in that it only 
contains seven negative-sense genomic RNA segments, and does not contain segments 
that code for either the hemagglutinin (HA) or neuraminidase (NA) proteins. Instead, 
ICV contains an RNA segment that codes for the hemagglutinin-esterase fusion (HEF) 
glycoprotein. This HEF glycoprotein facilitates the function of both the HA and NA 
proteins of IAV and IBV [61]. Additionally, ICV produces an alternative matrix protein 2 
when compared to IAV or IBV, called CM2 [51]. ICV primarily infects humans and has 
no animal reservoir, though it has been isolated from infected swine and dogs [34, 49, 
60]. It is not a pandemic capable virus, though isolated outbreaks can occur, often among 
children [35, 49]. Infection in humans usually occurs early in life, causes mild cold-like 
symptoms, and the host develops broadly neutralizing antibodies that usually prevent 
future infection of any other ICV variant [29, 34]. When serological surveillance was 
conducted on human populations, one in 1992 in France and another during 2000 in 
Brazil, high percentages of samples tested showed antibody titers consistent with past 
infection with ICV [33, 37]. Multiple lineages of ICV appear to co-circulate at any given 
time, and do exhibit re-assortment [39, 49].  
2. Novel Influenza D Virus 
 In 2011, a viral sample was isolated from diseased swine in Oklahoma that 
shared 50% homology with known ICV samples, and was originally designated a 
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separate strain of ICV. Upon further investigation and more sample isolation, it was 
determined that the samples isolated from swine and bovine hosts represented a new 
genus of the Orthomyxoviridae virus family due to the lack of in vitro re-assortment 
between human ICV samples and the newly isolated animal viruses [23]. Additionally, 
the newly isolated viruses expressed a unique splicing strategy for the production of the 
M1 protein [23]. The new genus was named influenza D (IDV) in 2013 and officially 
accepted by the scientific community as a novel virus genus [32]. Similar to ICV, it has a 
seven-stranded, segmented, negative-sense RNA genome. IDV is closely related to ICV 
and expresses the HEF glycoprotein instead of HA and NA proteins found on IAV and 
IBV [23]. Since its discovery, serological surveillance of human and animal populations 
has shown evidence of infection with IDV. Its primary reservoir appears to be cattle 
herds, and it has been isolated from or detected in bovine populations living in multiple 
countries around the world [8, 9, 14, 15, 23, 32, 38, 58]. Other animal species have been 
shown to be vulnerable to infection, including sheep, goats, swine, ferrets, and guinea 
pigs [50]. Serological evidence of infection has also been detected in humans who work 
closely with cattle [58].  
Influenza D Virion Structure 
 All influenza viruses exhibit a spherical particle shape composed of a host-cell 
derived lipid membrane with embedded viral surface protein spikes. The virion structure 
of IDV is very similar to that of ICV. Like ICV, IDV particles express two surface 
proteins: hemagglutinin-esterase fusion protein (HEF) and CM2. Beneath the lipid 
membrane the viral structure is made up of a layer of matrix protein 1 (M1) that connects 
the outer membrane with the inner components of the particle. Within the matrix layer of 
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the virion lies the negative-sense RNA genome surrounded by nucleoprotein (NP), and 
attached to each segment of the RNA genome is an RNA dependent RNA polymerase 
complex. This polymerase complex is a trimeric complex made up of three proteins: 
polymerase base 1 (PB1), polymerase base 2 (PB2), and polymerase 3 (P3). Each 
genomic RNA segment and its attached RNA polymerase complex is surrounded by the 
NP protein to form a structure called the viral ribonucleoprotein (RNP) complex.  
Influenza D Genome Structure 
 The influenza D genome is composed of seven negative-sense single stranded 
RNA segments. These seven genomic segments produce the nine proteins that make up 
the IDV particle structure and life cycle.  
 The three largest segments code for the three proteins that make up the trimeric 
RNA polymerase complex: PB1, PB2, and P3. The next largest segments codes for the 
HEF surface protein. The fifth segment of the genome codes for the NP protein.  
 The sixth genomic segment produces two proteins, the first being the M1 
protein that is produced via mRNA splicing. Influenza D is distinguishable from ICV in 
its M1 splicing method. ICV splices the mRNA of the sixth segment by introducing a 
termination codon consisting of nucleotides 752, 753, and 982. In contrast, the IDV 
modifies this splicing strategy for M1 production by adding an additional 4-amino-acid 
peptide into the preceding exon [23]. The second is the DM2 protein, which is 
synthesized by the cleavage of the protein produced from the un-spliced mRNA of the 
sixth segment.  
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 The seventh genomic segment produces non-structural proteins, called 
nonstructural protein 1 (NS1) and nonstructural protein 2 (NS2). NS1 is produced 
directly from the seventh segment, while NS2 is produced via mRNA splicing. IDV is 
similar to other influenza viruses in its NS2 splicing strategy, but it does produce 
uniquely spliced sequences [23].  
Influenza C and D Life Cycle 
 Due to the fact that IDV has only recently been characterized and described, 
little is known about the details of its life cycle. As stated above, IDV is most closely 
related to ICV, and therefore it can be assumed that IDV’s life cycle will most closely 
resemble that of ICV’s. Among other influenza viruses, IDV shares the most structural 
and genetic traits with ICV, and as more work is done to fully characterize the life cycle 
of IDV, it is likely that many aspects will resemble those found in ICV. The following 
section will detail the life cycle of ICV, and what is currently known of the IDV life 
cycle.  
 Like all influenza viruses, the life cycle of influenza C begins with attachment 
of the viral particle to a host cell [42]. The major surface glycoprotein of ICV, 
hemagglutinin-esterase fusion (HEF) protein, mediates the binding of the virus particle to 
the host cell by recognizing the sialic acid 9-O-acetyl-N-acetylneuraminic acid (9-O-Ac-
Neu5Ac) on the surface of epithelial cells [48]. Cells expressing 9-O-Ac-Neu5Ac can be 
found in the respiratory systems of numerous mammal species, which may explain the 
broad species tropism seen with ICV [56]. 
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 Upon attachment to 9-O-Ac-Neu5Ac on the surface of the host cell, ICV must 
gain entry into the cell to continue the life cycle. The entry of the virus particle into the 
host cell likely occurs via clatharin-mediated endocytosis as reported for other influenza 
viruses [42]. Endocytosis and entry into the cytoplasm of the host cell requires a low pH 
environment in order to trigger the next step, cell membrane fusion. Fusion occurs when 
the cellular endosomal membrane fuses with the viral membrane, and is caused by a low 
pH environment within the endosome. The low pH environment is important to the fusion 
process because this induces a structural change in the HEF protein that is necessary for 
the continuation of the life cycle [17]. 
 The structurally changed HEF protein is cleaved by a host-cell trypsin-like 
protease to produce two subunit peptides called HEF1 and HEF2. After this, the amino 
terminus of HEF2 is exposed, allowing for its interaction with the endosomal membrane 
while its transmembrane domain is embedded in the viral membrane [48]. This 
interaction with the endosomal membrane allows for both the viral membrane and the 
endosomal membrane to fuse. Once the membranes have fused, the viral genome and its 
associated proteins can be released into the cytoplasm of the host cell.  
 Releasing the viral contents occurs via a process called uncoating. The 
uncoating process begins with a viral protein called CM2 acting as an ion channel into 
the interior of the viral particle. Ion channel CM2 allows for hydrogen ions from the 
endosomal compartment to flow into the virion, lowering the pH and disrupting 
interactions between multiple copies of the matrix protein 1 (M1) [51]. M1 serves as the 
internal structure of the virion and the uncoating process is completed by disrupting its 
interactions [42].  
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 Once the internal contents of the virion are released, the viral RNA genome is 
transported to the nucleus of the host cell to begin the process of replication. The RNA 
particles that are transported to the nucleus are surrounded by a protein called 
nucleoprotein (NP), and the viral nucleoprotein RNA complex is known as RNP [42]. 
Each viral RNA genome segment also has a RNA polymerase complex bound to its end. 
This complex is a trimer and is made up of three proteins known as polymerase basic 
protein 1 (PB1), polymerase base protein 2 (PB2), and P3. The RNA genome segments 
with their bound RNA polymerase complexes cannot passively diffuse into the nucleus of 
the host cell, and therefore require active transport through a nuclear pore. In order to be 
transported, the RNP/polymerase complex requires a nuclear localization signal that is 
located on the NP protein [52]. 
 To facilitate active transport into the nucleus of the cell, a cellular cargo 
protein must be recruited to the nuclear localization signal. An importin-family transport 
protein recognizes the signal carried on the NP protein and allows for the RNP complex 
to dock to the nuclear pore and be transported into the nucleus for RNA synthesis [52]. 
 Synthesis takes place via a two-step process involving the trimeric RNA 
polymerase complex. The first step is the transcription of messenger RNA (mRNA) from 
the imported viral RNA (vRNA), where each genomic sequence is transcribed via a 
primer dependent mechanism. After the mRNA is transcribed, a full-length positive-sense 
copy of each of the vRNA genomic sequences is synthesized. Known as complementary 
RNA (cRNA), these full-length copies serve as a template for the synthesis of additional 
vRNA genomic segments. Once new vRNA segments are synthesized they are 
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surrounded with NP proteins that will assist in the trafficking of the new RNP to the cell 
membrane [42].  
 The newly synthesized RNP must be exported from the nucleus, and this 
process is mediated by interactions between the NS2 viral protein and host nucleoporins. 
Once the RNP has exited the nucleus, they are trafficked to the site of viral assembly on 
the plasma membrane. Once the RNP has exited the nucleus, it travels to the site of viral 
assembly, which is made up of lipid rafts coming together on the host cell membrane [42, 
52]. The transportation of the RNP to the plasma membrane is thought to be mediated by 
interactions between the M1 and other viral proteins [17, 51].  
 The major surface proteins HEF and CM2 are also required for assembly to 
complete. These proteins are associated into the lipid raft after they are synthesized. 
Synthesis of HEF and M2 takes place in the cellular endoplasmic reticulum (ER), where 
they are properly folded and, in the case of HEF, glycosylated [17, 42]. The HEF proteins 
are then associated into the trimeric protein spike structure and the CM2 proteins are 
assembled into tetramers. After folding and glycosylation, the proteins undergo further 
modification in the trans-Golgi network to prepare them for association into the cellular 
membrane [17]. The HEF and CM2 proteins are directed toward the site of viral 
assembly by sorting signals contained in both proteins, in addition to the sorting signals 
each protein contains a signal that directs its association into the lipid rafts that are part of 
the host cell membrane [51, 52]. These lipid rafts act as the site of virion assembly and 
are rich in cholesterol and sphingolipids, components important to the construction of the 
virus particle. Once the proteins have been sorted, HEF is directly incorporated into the 
lipid raft while CM2 binds with cholesterol molecules that are part of the lipid raft [17]. 
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The binding of CM2 to the cholesterol is thought to aid in virion construction by linking 
together multiple lipid raft domains on the cell membrane. The CM2 protein is also 
important in the incorporation of RNP into the developing virion, and virus lacking in 
CM2 protein developed particles without genomic RNA segments incorporated [17, 51].  
 The next steps in viral assembly are currently less understood. The current 
hypothesis is that M1 protein acts as a recruiting signal for non-structural viral proteins as 
well as the RNP genetic core [42, 52]. The M1 protein itself lacks a membrane targeting 
signal, so it is hypothesized that the M1 protein interacts in some way with the HEF 
protein for correct membrane targeting [42]. The M1 recruiting signaling is thought to 
bring the additional components to the site of viral assembly to fully complete the 
recruitment of viral proteins.  
 Once all of the viral proteins and the RNP are recruited and integrated into the 
host membrane, the process of budding begins. Budding is the outward curving of the 
host cell membrane that eventually leads to the new virus particle releasing [51]. The 
current model of influenza budding describes the process beginning with the 
incorporation of viral proteins into the host cell membrane lipid rafts. This leads to the 
clustering of lipid rafts at the site of viral assembly as more viral proteins are integrated, 
causing the membrane to deform [17, 42]. The deformation of the membrane allows for 
the cytoplasmic tails of the viral proteins to interact, recruiting the RNP genetic core as 
well as other non-structural viral proteins to the budding virion. As more proteins are 
recruited and incorporated, the deformation becomes more pronounced until the new 
virion is ready to cut away from the host cell in a process called scission [42, 52]. The 
CM2 protein is thought to play a critical role in this process [51]. Finally, after scission is 
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achieved, the esterase activity of the HEF surface protein may be required to cleave the 9-
O-acetyl group from 9-O-Ac-Neu5Ac to fully release the new virion from the host cell 
membrane surface [48].    
3. Serological Surveillance 
 Viruses that pose a risk to human or animal health are often under surveillance 
in order to track the prevalence, variety, changes, and locations of infections [1, 19, 25, 
55]. Influenza is under constant surveillance around the world to track changes in the 
currently circulating virus varieties, determine where outbreaks will occur, and determine 
the best possible combination of vaccine candidates for the yearly influenza vaccination 
[7].  
 Surveillance can be accomplished via serological methods of detecting 
antibodies in animal samples, genomic sequencing of viral samples, detection of RNA 
expression, or tracking reports of infection [1, 35, 40, 53]. The World Health 
Organization (WHO) provides researchers and health workers with a reference guide for 
the correct conduction of influenza surveillance, titled “Manual for the laboratory 
diagnosis and virological surveillance of influenza”, and the American Center for Disease 
Control (CDC) provides an overview on their website of their current efforts in 
monitoring influenza activity in the USA and around the globe [1, 7].  
 The active monitoring and documentation of influenza is an on-going global 
project, and with the recent discovery of the novel genus influenza D, that work must be 
expanded to include fully elucidating the host range of the potentially harmful new virus. 
By broadening our understanding of what species of animal are capable of carrying IDV, 
we can better assess the risks the disease poses to human health and economy.  
12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 2: Serological evidence for the co-circulation of two lineages of 
influenza D virus in equine populations of the Midwest United States  
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Background 
The Orthomyxoviridae virus family has three influenza genera, A, B, and C, which 
are classified according to antigenic differences in their nucleoprotein and matrix proteins 
[42]. The fourth genus of influenza, named influenza D, has been recently described 
(https://www.cdc.gov/flu/about/viruses/types.htm). Influenza D (IDV) represents a novel 
type of virus more closely related to influenza C (ICV) than influenza A (IAV) or influenza 
B (IBV). IDV uses bovine as its primary reservoir, and has been isolated from cattle herds 
from multiple countries including: China, France, Italy, and the United States [8, 22, 28]. 
Susceptibility to infection by this novel virus has also been demonstrated in swine, sheep, 
goats, guinea pigs, and ferrets [43, 50]. In addition, serological evidence for IDV infection 
in humans has been recently established [58]. 
The worldwide prevalence and broad species tropism of this new influenza virus 
represents a growing potential threat to humans and other agricultural species. Many 
species are vulnerable to influenza infection, including humans; therefore, it is important 
to identify other potential hosts of this novel type. The primary goals of this study were to 
investigate the seroprevalence of IDV in American equine populations by conducting 
multiple serological surveys, as well as studying the antibody prevalence in this animal 
host of human ICV, which is closely related to IDV.  
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Materials and Methods 
2.1 Cell culture, reference serum, and virus production 
 Madin-Darby canine kidney (MDCK) cells (ATCC) were cultured using 
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine 
serum (PAA Laboratories Inc., Dartmouth, MA, USA) and 1% streptomycin and penicillin 
(Life Technologies, Carlsbad, CA, USA).  Isolated from bovine and swine presenting 
respiratory disease symptoms, influenza D/bovine/Oklahoma/660/2013 (D/660) and 
D/swine/Oklahoma/1334/2011 (D/OK) were grown on MDCK cells at 0.01 MOI and 
incubated at 37ºC with 5% CO2 for at least 5 days.  D/OK and D/660 are representative 
strains of two antigenic lineages of IDV, D/OK being of swine origin and D/660 being of 
cattle origin. These two viruses have been found to be antigenically different lineages of 
IDV, likely due to their host divergence [23]. Influenza C/human/Johannesburg/1/1966, 
originally isolated from humans, was produced in the same manner.  
To better promote viral growth, DMEM maintenance media was supplemented 
using 1 g/mL tosylsulfonyl phenylalayl chloromethyl ketone (TPCK) trypsin (Sigma, St. 
Louis, MO, USA) and 1% penicillin and streptomycin (Life Technologies, Carlsbad, CA, 
USA).  Virus titer (TCID50 per ml) was measured using both the Reed and Muench’s 
method and the hemagglutination assay as described in the W.H.O. standard 
manual[45](www.who.int/influenza/en/).  
Reference serum was generated against the three influenza virus strains via rabbit 
immunization in lab at SDSU (IACUC # 16-027A) and at the Covance Research Products. 
Covance produced the D/OK reference serum, the D/660 and C/JHB serum was produced 
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at SDSU. All groups used a nearly identical method of generation involving 
hyperimmunization of immune-competent rabbits with UV-inactivated virus of the desired 
lineage formulated in adjuvant. The rabbits were immunized via both the intramuscular 
and subcutaneous routes. Serum was purified from blood drawn from the rabbits 
periodically throughout the generation procedure.   
 
2.2 Serology 
Hemagglutination inhibition (HI) and MDCK-based Microneutralization (MN) 
assays were employed as described in the WHO standard manual and previous literature to 
detect antibody titers [44](www.who.int/influenza/en/), with minor revisions to the MN 
assay for use with ICV and IDV. Our revision for the MN assay was that virus is cultured 
on MDCK cells in 96 wells plates in the presence of serially-diluted serum for 120 hours 
(5 days) to insure that the slow growing ICV and IDV viruses could reach a detectable titer 
level if they hadn’t been neutralized by the antibodies present in the serum. For the 
assessment of titer, Turkey red blood cells (Lampire Biological Laboratories, Pipersville, 
PA, USA) were used in both the HI and MN assays.  For both the MN and HI assays, a 
titer of 40 was used as the threshold to describe a positive sample in accordance to the 
WHO protocols and an additional confirmation study(www.who.int/influenza/en/)[59].  HI 
and MN assays were tested in duplicate and HI or MN titers were described as the 
reciprocal of the final serum dilution that blocks viral ability to agglutinate red blood cells 
or inhibit viral replication, respectively. All samples were assayed in three separate 
experiments, and the antibody titers were determined as the mean of these triplicate data.  
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2.3 Serum sample collection 
 364 equine samples were collected during the summer of 2015 from farms and 
ranches in six states; Iowa (IA), Minnesota (MN), North Dakota (ND), Nebraska (NE), 
South Dakota (SD), and Wyoming (WY). These states occupy a generally north-central 
location of the continental United States of America and share numerous borders with each 
other. These samples were collected through the Animal Disease Research and Diagnostic 
Laboratory at South Dakota State University (SDSU).  A further 100 equine samples were 
collected during the summer of 2016 again through the ADRDL at SDSU.  The 100 
samples were collected from horses from farms or ranches in Iowa (IA), Minnesota (MN), 
Nebraska (NE), and South Dakota (SD). Anti-sera against two IDV lineages (D/OK and 
D/660) and one human ICV (C/JHB) was generated from rabbits via immunization as 
described above, and collected for use as antibody controls and for the purpose of testing 
cross-reactivity between ICV and IDV. 
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Results and Discussion 
We first investigated the potential cross-reactivity between IDV and ICV by the HI 
assay. Rabbit reference antisera to two IDV lineages, Influenza D/swine/OK/1334/2011 
(D/OK) and Influenza D/bovine/660/2013 (D/660), and one human ICV, Influenza 
C/Victoria/2/2012 (C/Vic), as well as negative-control sera, were tested. Two IDV lineage-
representative viruses, D/OK and D/660 as above, and one human ICV, C/Vic as above, 
were used in the HI cross-reactivity assay.  As summarized in Table 1, the antiserum for 
the D/660 strain was equally reactive to the D/660 virus and the D/OK virus with an HI 
titer of 1280 against both, while having no detectable reactivity with C/Vic. Furthermore, 
the antiserum generated against the D/OK strain was more specific to the D/OK virus, with 
a HI titer of 2560, but was also cross reactive with D/660 with a titer of 640. The antiserum 
generated against C/Vic was specific to the C/Vic virus with a HI titer of 2560 with no 
detectable activity with either IDV lineage. These results confirmed the specificity of our 
HI assay in the detection of anti-IDV antibodies, demonstrating that it could be used for 
screening of equine serum samples for antibodies to IDV and ICV. As described below, 
the possibility of a similar cross-reactive relationship between D/OK and D/660 within 
equine populations is observed. 
Bovine, swine, and small ruminant species are known to host IDV [43]. To 
determine if the equine population is susceptible to IDV, we tested 364 horse serum 
samples gathered in 2015 from six states (IA, MN, ND, NE, SD, WY), as well as 100 more 
samples gathered in 2016 from four states (IA, MN, NE, SD). All of the above samples 
were also analyzed for the presence of ICV antibodies. All samples were tested for virus 
specific antibodies via the standard hemagglutinin inhibition assay (HI) in triplicate. Any 
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serum sample with an average antibody titer greater than or equal to 40 was considered 
positive for antibodies against that given virus species. 
Table 2 details a subset of the HI data from serum samples collected in 2015. Serum 
samples were grouped by farm of origin, and any farm that was the origin of more than one 
serum sample and had at least one serum sample test positive for antibodies against at least 
one of the viral lineages is included in the table. Of the 141 farms that serum was collected 
from, 47 of them are included in this table. HI data is provided for all three virus lineages 
tested, and is detailed by one column containing the number of positive serum samples 
originating from that farm followed by the total number of samples originating from that 
farm. A second column details the average titer value of the positive samples originating 
from that farm. The state of the United States in which the farm resides is also included 
with the serological data. Of the 230 individual serum samples included in the table, 36 
tested positive for antibodies against D/OK, 28 tested positive for antibodies against D/660, 
and 37 tested positive for antibodies against C/JHB.  
Farms only represented by one serum sample are not detailed on this table, but the 
data is as follows: of the 74 single-sample farms, 16 serum samples were positive for 
antibodies against at least one virus. Of these, 8 were positive for antibodies against D/OK, 
11 were positive for antibodies against D/660, and 4 were positive for antibodies against 
C/JHB.  
It should be noted that of 57 total positive samples to IDVs for 2015 serum samples, 
23 (23/364; 6.3%) of them were positive for both IDV lineages (D/OK and D/660), while 
21 (21/364; 5.8%) and 13 (13/364; 3.6%) tested positive for only D/OK or D/660 lineage, 
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respectively. Based on the cross-reactivity data of two IDV lineages generated against 
reference rabbit antiserum (Table 1), we speculated that the 23 horses with detectable 
antibodies to both lineages were infected largely by D/660 or D/660-like viruses because 
D/660 antisera recognized both lineages equally well in the HI assay. Furthermore, our 
observation that 21 horses possessed antibodies only to D/OK seemed to indicate that these 
animals were infected by D/OK or D/OK-like viruses because rabbit antiserum specific for 
D/OK has a 4-fold higher HI antibody titer to the D/OK than D/660 (Table 1). Interestingly, 
we also found 13 horses only seropositive to the D/660 lineage. We suspect that these 
animals may have been exposed to a D/660-like virus, which may have evolved some 
mutations abolishing epitopes common to the two lineages tested (D/660 and D/OK). A 
recent study in Japan has provided some preliminary evidence supporting for the existence 
of a potential third lineage of IDV [38]. It is also possible that the samples positive for both 
lineages of IDV could be exhibiting super-infection or co-infection of both D/660 and 
D/OK. This is difficult to determine due to both the cross-reactive nature of these viral 
lineages as well as our lack of temporal data related to the samples collected. These 
hypotheses will be investigated in future studies. In summary, the results of our serology 
study demonstrated that multiple lineages of IDV already infected horses in the 
Midwestern region, and that there is possibly some element of super-infection, co-
infection, and/or cross-reactivity between the two IDV lineages studied, or there is the 
potential for the presence of an unidentified IDV lineage related to both D/OK and D/660 
circulating among horses.  
 In Fig. 1, we graphed a 2-D scatterplot containing all 2015 samples from the HI 
trials that tested positive for at least one of the two IDVs (D/OK and D/660) and one ICV. 
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The correlation coefficients show that there is strong positive correlation between the 
antibody titers of the two IDV lineage viruses (D/660-D/OK), with an R value of .541 and 
a P of 1.53x10-8. Interestingly, we also found negative correlations between the antibody 
titers found for our ICV strain and the two IDV strains, with an R of -.364 and a P of 
2.86x10-4 between C/JHB and D/660, and an R of -.435 and a P of 1.06x10-5 between 
C/JHB and D/OK. 
 In addition to 2015 serum samples, we also collected 100 horse serum samples in 
2016 to determine the presence of IDV- or ICV- specific antibodies. Compared with 2015 
serum samples deriving from aged horses, 2016 serum samples were largely from young 
ponies in SD and the region. Our result showed 3 (3/100, 3%) samples positive for 
antibodies against D/OK, 2 (2/100, 2%) samples positive for antibodies against D/660, and 
8 (8/100, 8%) samples positive for antibodies against C/JHB (data not shown). The 
discrepancies observed in the overall seroprevalence between the samples in 2015 and in 
2016 may be attributed to a much smaller samples size consisting of samples taken from a 
much narrower population of horses. The 2016 samples represent both fewer states and a 
much smaller total number of farms. 
 To further verify the results observed in the HI assays, the MN assay was used for 
a select subset of samples. Samples were chosen such that we could confirm both positive 
and negative results: MN sample groups were made of samples positive for multiple 
viruses, positive for just one virus, and positive for no viruses. As shown in Table 3 (2015 
samples) and Table 4 (2016 samples), the MN assay confirms the results found via HI 
assay. The titer threshold for confirming a positive sample was considered anything greater 
than or equal to 40 [43, 44]. Based on the MN results, the HI seroprevalence results appear 
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to be accurate for all three virus lineages, confirming the presence of IDV and ICV within 
American equine populations. It should be noted that despite the overall agreement 
between HI and MN assays several outliers were observed. For example, three samples 
(IDs# 4, 6, 21) in Table 3 and one sample (IDs# 19, 23), tested positive in the HI assay, did 
not contain measurable neutralizing antibodies in the MN assay. The discordance may be 
caused by suboptimal quality of these samples after the long-term storage process. We also 
found that some samples (IDs 4, 5, 17, 18, 21, and 22 in Table 3 and ID# 71 in Table 4) 
tested negative by HI, turned out to be positive in the MN assay. This inconsistency is 
likely due to more sensitive nature the MN assay offers in the antibody detection. Another 
possibility is that the MN assay could detect other functional antibodies within the horse 
serum, such as those blocking virus-cell fusion, that could not be detected by HI assay. 
 In summary, we presented serological evidence that equines are susceptible to IDV 
and ICV infections. A previous study had showed that ICV antibodies were present in 
horses [13]. Based on these findings, horses should be added into the host range of this 
novel influenza virus that already includes bovines, swine, sheep, and goats [8, 15, 28, 43]. 
Future surveillance of IDV in horse populations is needed, as well as more serological 
investigations into other species potentially susceptible to influenza viruses to determine 
the total host range of IDV.  
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Figures and Tables 
Table 1. Cross-reactivity of influenza C and D viruses by HI Assay   
D/OK D/660 C/Vic 
D/660 antiserum 1280 1280 <10 
D/OK antiserum 2560 640 <10 
C/Vic antiserum <10 <10 2560 
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Table 2. Equine serological surveillance of Influenza virus types C and D in 2015 
Farm 
ID Location 
D/OK D/660 C/JHB 
Positive\ 
Total 
Average 
Titer 
Positive\ 
Total 
Average 
Titer 
Positive\ 
Total 
Average 
Titer 
1 SD   6 \ 42 51.7 3 \ 42 46.7 14 \ 42 60 
2 SD 0 \ 13 − 0 \ 13 − 2 \ 13 40 
3 SD 1 \ 11 80 1 \ 11 40 0 \ 11 − 
4 SD 0 \ 9 − 1 \ 9 60 2 \ 9 60 
5 SD 2 \ 9 40 0 \ 9 − 0 \ 9 − 
6 SD 1 \ 7 40 0 \ 7 − 0 \ 7 − 
7 SD 1 \ 7 45 0 \ 7 − 1 \ 7 40 
8 SD 1 \ 6 60 0 \ 6 − 0 \ 6 − 
9 SD 0 \ 5 − 0 \ 5 − 1 \ 5 40 
10 SD 1 \ 5 40 0 \ 5 − 0 \ 5 − 
11 SD 2 \ 5 80 2 \ 5 50 0 \ 5 − 
12 SD 1 \ 5 45 0 \ 5 − 0 \ 5 − 
13 SD 0 \ 5 − 0 \ 5 − 1 \ 5 40 
14 SD 1 \ 5 80 1 \ 5 80 0 \ 5 − 
15 MN 2 \ 4 70 2 \ 4 80 0 \ 4 − 
16 SD 0 \ 4 − 0 \ 4 − 2 \ 4 − 
17 SD 0 \ 4 − 1 \ 4 40 0 \ 4 − 
18 NE 0 \ 4 − 0 \ 4 − 1 \ 4 40 
19 MN 4 \ 4 70 4 \ 4 60 0 \ 4 − 
20 SD 0 \ 4 − 0 \ 4 − 1 \ 4 40 
21 NE 1 \ 4 50 0 \ 4 − 0 \ 4 − 
22 SD 0 \ 4 − 1 \ 4 45 0 \ 1 − 
23 SD 1 \ 4 60 1 \ 4 80 0 \ 4 − 
24 SD 1 \ 4 60 1 \ 4 40 0 \ 4 − 
25 SD 1 \ 4 40 1 \ 4 45 0 \ 4 − 
26 SD 0 \ 4 − 0 \ 4 − 1 \ 4 40 
27 NE 0 \ 3 − 0 \ 3 − 0 \ 3 − 
28 SD 1 \ 3 40 0 \ 3 − 0 \ 3 − 
29 SD 0 \ 3 − 0 \ 3 − 1 \ 3 40 
30 SD 1 \ 3 60 2 \ 3 70 0 \ 3 − 
31 SD 0 \ 3 − 1 \ 3 80 0 \ 3 − 
32 SD 0 \ 3 − 1 \ 3 40 0 \ 3 − 
33 SD 1 \ 2 40 0 \ 2 − 0 \ 2 − 
34 WY 0 \ 2 − 0 \ 2 − 1 \ 2 40 
35 IA 0 \ 2 − 0 \ 2 − 1 \ 2 80 
36 SD 1 \ 2 60 0 \ 2 − 1 \ 2 40 
37 SD 0 \ 2 − 0 \ 2 − 2 \ 2 60 
38 SD 1 \ 2 40 0 \ 2 − 0 \ 2 − 
39 SD 0 \ 2 − 0 \ 2 − 1 \ 2 80 
40 SD 1 \ 2 40 0 \ 2 − 0 \ 2 − 
41 SD 1 \ 2 60 1 \ 2 80 0 \ 2 − 
42 SD 1 \ 2 80 1 \ 2 80 1 \ 2 40 
43 SD 1 \ 2 60 1 \ 2 40 0 \ 2 − 
44 SD 0 \ 2 − 0 \ 2 − 1 \ 2 40 
45 SD 0 \ 2 − 0 \ 2 − 1 \ 2 80 
46 SD 1 \ 2 80 1 \ 2 80 0 \ 2 − 
47 SD 0 \ 2 − 1 \ 2 40 1 \ 2 40 
Total   36 \ 230  28 \ 230   37 \ 230   
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Note: Only farms with at least one serum sample positive to at least one of the listed 3 viruses were included. This table did not 
include the farms that only had one sample. Each farm ID is accompanied by its location by state within the USA. For each farm, the 
number of samples positive to the virus over the number of total samples, and the average HI titer of the positive samples are shown. 
A “−“ indicates the samples were negative to the virus. 
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Table 3. Microtiter neutralization confirmation of the HI titers observed for serum samples 
in 2015 
 
A “− “ indicates the samples were negative to the virus. 
 
  
  D/OK D/660 C/JHB 
Sample 
ID 
HI MN HI MN HI MN 
1 80 80 80 160 − − 
2 − − − − − − 
3 80 80 80 160 − − 
4 40 − 40 40 − 80 
5 − − − 40 − − 
6 40 − − − − − 
7 − − − − − − 
8 80 160 80 80 − − 
9 80 40 − − − − 
10 − − − − − − 
11 − − − − − − 
12 − − − − − − 
13 − − − − − − 
14 − − − − − − 
15 − − − − − − 
16 − − − − − − 
17 − − − 40 − − 
18 − − − 40 − − 
19 − − − − − − 
20 60 40 80 40 − − 
21 40 − − 40 80 − 
22 − 80 60 40 − − 
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Table 4. Microtiter neutralization confirmation of the HI titers observed for serum 
samples in 2016  
D/OK D/660 C/JHB 
Sample ID HI MN HI MN HI MN 
6 60 160 80 160 − − 
11 − − − − − − 
12 − − − − − − 
13 50 80 40 80 − − 
19 − − − − 40 − 
21 − − − − 40 80 
23 − − − − 40 − 
25 − − − − 60 40 
30 − − − − 40 160 
32 − − − − 60 80 
71 − 80 40 40 − − 
91 − − − − 40 40 
92 − − − − − − 
93 − − − − − − 
A “− “ indicates the samples were negative to the virus. 
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Figure 1. A 2-D Scatter plot of all 2015 samples positive for at least one virus 
 
 
Figure 1. This figure includes all samples from the 2015 sample set that tested positive to 
at least one of the three viruses tested (D/OK, D/660, C/JHB). These are graphed along 
the x-axis. Each sample includes three data points, one to represent its tested average titer 
to each of the three viruses, with titer values graphed on the y-axis. The figure also 
includes the correlation measurements of the titer values for each virus taken against the 
others. The correlations show a strong positive relationship between the two IDV 
lineages (D/OK and D/660) and negative correlations between the ICV lineage and both 
IDV lineages. 
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Chapter 3: Summary and Conclusions 
Evidence has been presented that two lineages of influenza D virus (IDV) and one 
lineage of influenza C virus (ICV) are present in equine populations of the 
Midwestern United States. It has been shown that the antibody titer values measured 
in this serological study are not due to cross reactivity between ICV and IDV. Both 
D/bovine/Oklahoma/660/2013 (D/660) and D/swine/Oklahoma/1334/2011 (D/OK) 
had measurable antibody titers among some of the samples tested, with some samples 
testing positive for only one of the IDV lineage viruses while others showed antibody 
titers for both. A significant number of samples tested positive for antibodies against 
C/human/Johannesburg/1/1966 (C/JHB), a virus not previously described as being 
capable of infecting horses. The nature of ICV and IDV infection in horses needs to 
be further explored, especially in relation to close human contact. It needs to be 
determined if horses could potentially pose a health hazard to humans in relations to 
infection with these pathogens. The possibility of cross-species infection exists with 
other influenza families, and IDV broad species tropism could indicate its potential to 
jump from livestock to humans.  
The presence of samples positive for multiple viruses raises interesting questions 
about the exact nature of IDV infection in horses. Is there another strain of IDV 
circulating among the equine population that could produce antibodies that are cross-
reactive to both D/OK and D/660? Are horses experiencing super-infection or co-
infection of these two lineages of IDV? Further development of a lineage-specific 
diagnosis plus regular monitoring the equine population for IDV infection will 
provide more clear information on what exactly the relationship between strains of 
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IDV is, and how that relationship effects the threat the disease poses to livestock and 
humans. The titer values observed also suggest that horses are vulnerable to active 
infection with IDV, if this is the case are there clinical symptoms associated with IDV 
infection in horses? Future work will need to determine if horses are suffering 
significant morbidity or mortality because of IDV infection. If it is discovered that 
animals are becoming ill from these infections, treatment and prevention options will 
need to be assessed and developed to prevent further economic and health effects 
caused by IDV to equine industry. All of these issues will need to be addressed in 
future studies to further our understanding of this novel pathogen in equine 
populations.  
Further monitoring of IDV in horses can also help elucidate what evolutionary 
changes occurred to cause IDV to separate from its close relative ICV. The equine 
host population of this virus could be an important factor in determining how this 
strain of influenza developed into a unique family of viruses. Ongoing surveillance of 
IDV in horse can also be used to track future evolutionary changes, as it may be 
possible for IDV to be more prone to genetic changes than the relatively stable ICV 
family. 
Further work will also need to include the exploration of additional species as 
potential hosts for IDV. This project provided more data to expand our understanding 
of what animals are vulnerable to this infection, but there still exists the potential for 
more unexamined species to harbor IDV.    
In conclusion, evidence has been shown that this newly discovered species of 
influenza virus is present in equine populations. The exact nature of this virus-host 
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interaction is not fully understood, but future work can fully clarify what has been 
discovered through the work done on this thesis. 
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